Medicilon has been conducting comprehensive non-clinical research for ophthalmic drugs since 2013, with extensive experience from active pharmaceutical ingredients and formulations to pharmacodynamics, pharmacokinetics, and safety assessments, and has contributed to the approval of multiple ophthalmic drugs.
Medicilon preclinical ophthalmology research platform integrates advanced drug administration technologies and analytical methods, high-quality equipment, and a team of experienced R&D professionals. It provides customers with ophthalmic drug development needs with high-quality and efficient experimental research services, as well as professional support for registration applications and project management services. Medicilon preclinical ophthalmology research platform has completed multiple projects on the safety studies of ophthalmic formulations, including eye drops; and has conducted several projects on pharmacodynamic and pharmacokinetic studies for intravitreal injections, subretinal injections, and eye drops. It has also completed full sets of non-clinical research projects for new drugs such as ophthalmic solutions or intravitreal injections. Currently, we are conducting several projects for the pharmacodynamic, pharmacokinetic, and safety assessment of ophthalmic solutions and intravitreal injections.
For more info, contact:
Email: marshalma@medicilon.com Tel: +44 1223981791
Global Headquarters: 585 Chuanda Road, Pudong, Shanghai, 201299, China
UK Office: Ailla Future Business Centre, King's Hedges Road Cambridge, CB4 2HY
